Thus, the effects of oxidant treatments alone and in combination with specific target therapies directed against ErbB downstream signaling pathways were investigated to evaluate their potential combined benefits in the treatment of gastric cancer, with parallel analysis of the expression of the components of the BER system, to highlight potential interactions. The gene discussed is EGFR; the disease is gastric cancer.